Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.

Abstract

Ann Oncol 2018; 29: i28–i37 (doi:10.1093/annonc/mdx705) In the original article, the sentence “Occurrence of grade 3 and 4 interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab [73], …” Has been corrected to “Occurrence of interstitial lung disease has been reported in 38% (13/34) of patients exposed to the combination of osimertinib plus durvalumab, of which five were of grade 3 and 4 [73], …”. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancerAnnals of OncologyVol. 29PreviewLung cancer represents the leading cause of cancer-related deaths worldwide. Despite great advances in its management with the recent emergence of molecular targeted therapies for non-small-cell lung cancer (NSCLC), relapse of the metastatic disease always occurs within approximately one year. Epidermal growth factor receptor (EGFR) mutant tumours are the prime example of oncogene addiction and clonal evolution in oncology, regarding the emergence of resistance to first- and second-generation EGFR inhibitors. Full-Text PDF Open Archive